Ribavirin - current status of a broad spectrum antiviral agent

Bibliography

• WITKOWSKI J, ROBINS R, SID WELL R, SIMON L: The design, synthesis, and broad spectrum antiviral activity of 1-I3-D-ribofuranosy1-1, 2, 4-triazole-3-carboxamide and related nucleosides. j. Med. Chem. (1972) 15:1150–1154.
   PubMed Web of Science ®Google Scholar
• SID WELL R, HUFFMAN J, KHARE G, ALLEN L, WITKOWSKI J, ROBINS R Broad-spectrum activity of Virazole: 1-I3-D-ribofuranosy1-1, 2, 4-triazole-3-carboxamide. Science (1972) 177:705–7–6.
   Google Scholar
• SID WELL R, REVANKAR G, ROBINS R: Ribavirin: review of a broad-spectrum antiviral agent. In: Viral Chemotherapy Vol 2 (fiternational Ericydopaerlia of Pharmacology and Therapeutics Section 116). Shugar D, (Ed.), Pergamon Press, Oxford, UK (1985):49–108.
   Google Scholar
• FERNANDEZ H, BANKS G, SMITH R: Ribavirin: a clinical overview Eur firidemiol. (1986) 2:1–14.
   Google Scholar
• PATERSON J, FERNANDEZ-LARSSON R: Molecular mechanisms of action of ribavirin. Rev. Infect. Dis. (1990) 12:1139–1146.
   PubMedGoogle Scholar
• CROTTY S, MAAG D, ARNOLD J et a/.:The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nature Med. (2000) 6:1375–1379.
   Google Scholar
• SAUNDERS J, RAYBUCK S: Inosine monophosphate dehydrogenase: consideration of structure, kinetics, and therapeutic potential. Annu. Rep. Med. Chem. (2000) 35:201–210.
   Google Scholar
• SCHEIDEL L, STOLLAR V: Mutations thatconfer resistance to mycophenolic acid and ribavirin in Sindbis virus map to the nonstructural protein nsPl. Virology (1991) 181:490–499.
   PubMedGoogle Scholar
• ERIKSSON B, HELGSTRAND E, JOHANNSON N et al.: Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents Chemother. (1977) 11:946–951.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-LARSSON R, PATTERSON j: Ribavirin is an inhibitor of human immunodeficiency virus reverse transcriptase. Mal Pharmacol. (1990) 38:766–770.
   PubMed Web of Science ®Google Scholar
• HEAGY W CRUMPACKER C, LOPEZ E FINBERG R: Inhibition of immune functions by antiviral drugs. j. CM]. Invest. (1991) 87:1916–1924.
   PubMedGoogle Scholar
• NAKANO K, CINADER B: Effect of 1-13-D-ribofuranosyl-1, 2, 4-triazole-3- carboxamide (ribavirin) on tolerance induction in SJL mice. Immurropharmacology (1980) 2:157–164.
   PubMedGoogle Scholar
• JOLLEY W, CALL T, ALVORD L, HINSHAW D: Immunosuppressive activity of ribavirin using the rabbit skin allograft model. Ann. N.Y Acad. Sci. (1977) 284:230–232.
   PubMedGoogle Scholar
• KOUROUNAKIS L, YOUNG-RODENCHUCK M, KAPUSTA M: Virazole and adjuvant-induced disease in rats. Arthr. Rheum. (1977) 20:1032.
   PubMedGoogle Scholar
• KLASSEN L, BUDMAN D, WILLIAMS G, STEINBERG A, GERBER N: Ribavirin: efficacy in the treatment of murine autoimmune disease. Science (1977) 195:787–789.
   PubMedGoogle Scholar
• POWERS C, PEAVY D, KNIGHT V: Selective inhibition of functional lymphocyte subpopulations by ribavirin. Antimicrob. Agents Chemother. (1982) 22:108–114.
   PubMedGoogle Scholar
• HULTGREN C, MILICH D, WEILAND O, SALLBERG M: The antiviral compound ribavirin modulates the T helper (Tffil/Th2 subset balance in hepatitis B and C virus-specific immune responses. j. Cm Viral. (1998) 79:2381–2391.
   Google Scholar
• NING Q, BROWN D, PARODO J etal.: Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fg12 prothrombinase and preserves Thl cytokine production but inhibits Th2 cytokine response. j. Immune]. (1998) 160:3487–3493.
   Google Scholar
• BERGAMINI A, BOLACCHI F, CEPPARULO Metal.: Treatment with ribavirin and interferon-a reduces interferon-gamma expression in patients with chronic hepatitis C. Clin. Exp. Lumina. (2001) 123:459–464.
   Google Scholar
• ARENA A, MERENDINO R, LIBERTO M,MANCUSO G, BONINA L, MASTROENI P: Combined effects of ribavirin and mononuclear phagocytic cells on virus replication. bit .j Immunother (1987) 3:313–317.
   Web of Science ®Google Scholar
• STEELE R, CROSBY D, STEELE R, PILKINGTON N, CHARLTON R: Effects of ribavirin on neutrophil function. Am. j. Med. Sci. (1988) 295:503–506.
   PubMed Web of Science ®Google Scholar
• ROSNER I, WELLIVER R, EDELSON P, GERACI-GIARDULLO K, SUN M: Effect of ribavirin therapy on RSV-specific IgE and IgA responses after infection. j. Infect. Dis. (1987) 155:1043–1047.
   PubMedGoogle Scholar
• MARQUARDT D, GRUBER H, WALKER L: Ribavirin inhibits mast cell mediator release. j. Pharmacol. Exp. Ther (1987) 240:145–149.
   PubMedGoogle Scholar
• KHAN A, KITSUTANI E CORNELI A: Hantavirus pulmonary syndrome in the Americas: the early years. Sem. Respir Grit. Cam Med. (2000) 21:313–322.
   PubMedGoogle Scholar
• HUGGINS J: Prospects for treatment of viral haemorrhagic fevers with ribavirin, abroad-spectrum antiviral drug. Rev Infect. Dis. (1989) 11 (Suppl. 4):s750–s761.
   Google Scholar
• JORDAN I, BRIESE T, FISCHER N, LAN J, LIPKIN W: Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells...J.1/1feet. Dis. (2000) 182:1214–1217.
   Google Scholar
• BERNIER R, TREMBLAY M, TSOUKAS C, BERGERON M: Drug sensitivity of human immunodeficiency virus type 1 isolates after ribavirin therapy. j. Infect Dis. (1997) 175:176–178.
   PubMedGoogle Scholar
• PARONI R, DEL PUPPO M, BORGHI C, SIRTORI C, KIENLE M: Pharmocokinetics of ribavirin and urinary excretion of the major metabolite 1, 2, 4-triazole-3-carboxamide in normal volunteers. Int. j.Pharmacol.Ther Taxied. (1989) 27:302–307.
   Google Scholar
• LASKIN O, LONGSTRETH J, HART C et al.: Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Glitz Pharmacol. Ther (1987) 41:546–555.
   Google Scholar
• LERTORA J, REGE A, LACOUR J etal.: Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients with human immunodeficiency virus. Clin. Pharmacol. Ther (1991) 50:442–449.
   Google Scholar
• KHAKOO S, GLUE E GRELLIER L etal.: Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. BE j. Cl/n. Marmara. (1998) 46:563–570.
   Google Scholar
• PAGE T, CONNOR J: The metabolism of ribavirin in erythrocytes and nucleated cells. bit.j Biochem. (1990) 22:379–383.
   Google Scholar
• KRAMER T, GAAR G, ROY C, MINNICH L, COPELAND J, CONNOR J: Hemodialysis clearance of intravenously administered ribavirin. Antimicrob. Agents Chemother. (1990) 34:489–490.
   PubMedGoogle Scholar
• CONNOR E, MORRISON S, LANE J, OELSKE J, SANKE R, CONNOR J: Safety Tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. Antimicrob. Agents Chemother (1993) 37:532–539.
   PubMedGoogle Scholar
• OGLE J, TOLTZIS P, PARKER W et al: Oral ribavirin therapy for subacute sclerosing panencephalitis. j Infect. Dis. (1989) 159:748–750.
   PubMedGoogle Scholar
• CONNOR J: Ribavirin pharmacokinetics. Pedlar': Infect. as. J. (1990) 9 (Suppl.):s91–s92.
   Google Scholar
• FRASCHINI I SCAGLIONE I MATERNAG etal.: Ribavirin influence on theophylline plasma levels in adults and children. Int. j. Glitz Pharmacol Ther Taxied. (1988) 26:30–32.
   Google Scholar
• SINNOTT J, CULLISON J, SWEENEY M, HAMMOND M, HOLT D: Respiratory syncytial virus pneumonia in a cardiac transplant recipient. j. Infect. Dis. (1988) 158:650–651.
   PubMedGoogle Scholar
• VOGT M, HARTSHORN K, FURMAN P et al.: Ribavirin antagonises the effect of azidothymidine on HIV replication. Science (1987) 235:1376–1379.
   PubMed Web of Science ®Google Scholar
• HARTMAN N, AHLUWALIA G, COONEY D et al.: Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2'3'-dideoxyadenosine and 2'3'-dideoxyinosine. Mel Marmara. (1991) 40:118–124.
   Google Scholar
• JOHNSON E: The effects of ribavirin on development and reproduction: a critical review of published and unpublished studies in experimental animals. J. Am. Coll Taxied. (1990) 9:551–561.
   Google Scholar
• KIRSHON B, FARO S, ZURAWIN R, SAMO T, CARPENTER R: Favourable outcome after treatment with amantadine and ribavirin in a pregnancy complicated by influenza pneumonia. j. Repred. Med. (1988) 33:399–401.
   PubMed Web of Science ®Google Scholar
• ATMAR R, ENGLUND J, HAMMILL H: Complications of measles during pregnancy. Cl/n. Infect. Dis. (1992) 14:217–226.
   PubMed Web of Science ®Google Scholar
• KNIGHT V GILBERT B: Antiviral therapy with small particle aerosols. Eat: j Clin. ll/licrobiol. Infect. Dis. (1988) 7:721–731.
   PubMedGoogle Scholar
• ROBERTS R, LASKIN O, LAWRENCE J et al.: Ribavirin pharmocodynamics in high-risk patients for acquired immunodeficiency syndrome. Cl/n. Pharmacol. Ther (1987) 42:365–373.
   PubMedGoogle Scholar
• CANONICO P, KASTELLO M, SPEARS C, BROWN J, JACKSON E, JENKINS D: Effects of ribavirin on red blood cells. Toxkol. Appl. Pharmacol. (1984) 74:155–162.
   PubMed Web of Science ®Google Scholar
• SOLIS-HERRUZ0 J, CASTELLANO G, FERNANDEZ I, MUNOZ R, HAWKINS F: Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. j. Hepatol. (2000) 33:812–817.
   PubMedGoogle Scholar
• LAFEUILADE A, HITTINGER G, CHADAPAUD S: Increased mitochondrial toxicity with ribavirin in HIV/HCV co-infection. Lancet (2001) 357:280–281.
   PubMedGoogle Scholar
• CAPSEY L, JONES K, SNELL N: Safety and tolerance of nebulised ribavirin in clinical usage. Acta Therapeutica (1992) 18:133–147.
   Google Scholar
• VAN BEVER H, DESAGER K, VAN OHECK Water intoxication after nebulised tribavirin. Lancet (1995) 345:451.
   PubMedGoogle Scholar
• HANL,WILSONR,SLATERSetaL:bi vitro and in vivo effects of ribavirin on human respiratory epithelium. Thorax (1990) 45:100–104.
   PubMedGoogle Scholar
• LISS H, BERNSTEIN J: Ribavirin aerosol in the elderly. Chest (1988) 93:1239–1241.
   PubMedGoogle Scholar
• LINN W GONG H, ANDERSON K, CLARK K, SHAMOO D: Exposure of health-care workers to ribavirin aerosol: a pharmacokinetic study. Arch. Baykal]. filth. (1995) 50:445–451.
   Google Scholar
• RANDOLPH A, WANGE E: Ribavirin for RSV lower respiratory tract infection: a systematic overview Arch. Pediati: Adolesc. Med. (1996) 150:942–947.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ W: Management strategies for respiratory syncytial viral infections in infants. Pediatc (1999) 135 (Suppl.):s45–s50.
   Google Scholar
• EDELL D, BRUCE E, HALE K, EDELL D, KHOSHOO V: Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants. Pediatr: PuNona (1998) 25:154–158.
   Google Scholar
• EVERARD M, SWARBRICK A, RIGBY A, MILNER A: The effect of ribavirin to treat previously healthy infants admitted with acute bronchiolitis on acute and chronic respiratory morbidity Respic Med. (2001) 95:275–280.
   Google Scholar
• ENGLUND J, PIEDRA P, YOUNG-MIN A, GILBERT B, HIATT P: High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. j Pediatc (1994) 125:635–641.
   PubMed Web of Science ®Google Scholar
• GILBERT B, KNIGHT V: Ribavirin aerosol as the treatment for influenza. Drugs of Today (1990) 26:195–205.
   Google Scholar
• RODRIGUEZ W HALL C, WELLIVER R et al.: Efficacy and safety of aerosolised ribavirin in young children hospitalised with influenza: a double-blind, multicentre, placebo-controlled trial. ..J. Pediatc (1994) 125:1229–1135.
   Google Scholar
• SNELL N: The activity of ribavirin against the human immunodeficiency virus: a review of laboratory and clinical experience. Antiviral Chernother. (1991) 2:257–263.
   Google Scholar
• SNELL N, POCOCK S: A meta-analysis of placebo-controlled clinical trials of ribavirin in patients with HIV infection. VIII International Conference on AIDS. Amsterdam (1992). Abstract PuB 7523.
   Google Scholar
• ANONONYMOUS EDITORIAL: Ribavirin for HIV - continuing smoke, not much fire. Lancet (1991) 338:22–23
   PubMedGoogle Scholar
• GILSON R, SEMPLE M, GILLS, LOVEDAY C, TEDDER R, WELLER I: Lack of suppression by ribavirin of HIV viraemia. Lancet (1992) 339:1605–1606.
   PubMedGoogle Scholar
• DENES A, EBERT J, BERQUIST K, MURPHY B, MAYNARD J: Antiviral effects of Virazole in chronic Hepatitis B Surface antigen-sero positive chimpanzees. Aritlinicrob. Agents Chernother: (1976) 10:571–572.
   PubMedGoogle Scholar
• KEW M, SEPIEL H: Treatment of chronic hepatitis B virus infection with ribavirin. Br. Med. J. (1977) 1:904.
   PubMedGoogle Scholar
• JAIN S, THOMAS H, OXFORD J, SHERLOCK S: Trial of ribavirin for the treatment of HBsAg positive chronic lever disease. j Aritlinicrob. Chernother: (1978) 4:367–373.
   PubMedGoogle Scholar
• KAKUMU S, YOSHIOKA K, WAKITA T, ISHIKAWA T, TAKAYANAGI M, HIGASHI Y: Pilot study of ribavirin and interferon-3 for chronic hepatitis B. Hepatology (1993) 18:258–263.
   PubMed Web of Science ®Google Scholar
• REICHARD O, ANDERSSON J, SCHVARCZ R, WEILAND O: Ribavirin treatment for chronic hepatitis C. Lancet (1991) 337:1058–1061.
   PubMed Web of Science ®Google Scholar
• DI BISCEGLIE A, SHINDO M, FONG T- L etal.: A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology(1992) 16:649–654.
   PubMed Web of Science ®Google Scholar
• REICHARD O, NORKRANS G, FRYDEN A, BRACONIER J-H, SONNERBORG A, WEILAND O: Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet (1998) 351:83–87.
   PubMed Web of Science ®Google Scholar
• POYNARD T, MARCELLIN E LEES etal.: Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet (1998) 352:1426–1432.
   Google Scholar
• McHUTCHISON J, GORDON S, SCHIFF E eta].: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N ErigI j Med. (1998) 339:1485–1492.
   Google Scholar
• DAVIS G, ESTEBAN-MUR R, RUSTGI V etal.: Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N ErigI Med. (1998) 339:1493–1499.
   Google Scholar
• COLLIER J, CHAPMAN R Combination therapy with interferon-a and ribavirin for hepatitis C: practical treatment issues. BioDrugs (2001) 15:225–238.
   PubMed Web of Science ®Google Scholar
• MADDREY W: safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C - relapsed and treatment-naïve patients. Seminars Live r Dis. (1999) 19\(Suppl. 1):67–75.
   Google Scholar
• McHUTCHISON J, POYNARD T, HARVEY J, GARAUD J-J, ALBRECHT J: The effect of dose reduction on sustained response in patients with chronic hepatitis C receiving interferon alfa-2b in combination with ribavirin. Hepatology (2000) 32:223A.
   Web of Science ®Google Scholar
• DIETERICH D, WASSERMAN R, BRAU N, HASSANEIN T, BINI E, SULKOWSKI M: Once-weekly recombinant human erythropoetin (Epoetin Alfa) facilitates optimal ribavirin (RBV) dosing in hepatitis C virus (HCV) -infected patients receiving interferon a-2b (IFN)/RBV combination therapy Gastroenterology (2001) 120\(Suppl. 1):A–64.
   Google Scholar
• JAHRLING P, HESSE R, EDDY G, JOHNSON K, STEPHEN E: Lassa virus infection of rhesus monkeys: Pathogenesis and treatment with ribavirin. j Infect. Dis. (1980) 141:580–589.
   PubMed Web of Science ®Google Scholar
• MCCORMICK J, KING I, WEBB P et al.: Lassa fever: effective therapy with ribavirin. N Engl. J. Med. (1986) 314:20–26.
   PubMed Web of Science ®Google Scholar
• ENRIA D, BRIGGILER A, LEVIS S, VALLEJOS D, MAIZTEGUI I, CANONICO P: Tolerance and antiviral effect of ribavirin in patients with Argentine haemorrhagic fever. Antiviral Res. (1987) 7:353–359.
   PubMed Web of Science ®Google Scholar
• KILGORE E KSIAZEK T, ROLLIN P etal.:Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin Infect. as. (1997) 24:718–722.
   PubMedGoogle Scholar
• HUGGINS J, HSIANG C, COSGRIFF T etal.: Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of haemorrhagic fever with renal syndrome. J. Infea Dis. (1991) 164:1119–1127.
   Google Scholar
• CHAPMAN L, MERTZ G, PETERS C: Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during one year of open label experience. Antiviral Ther. (1999) 4:211–219.
   PubMed Web of Science ®Google Scholar
• MONATH T: Ribavirin, interferon, and antibody approaches to prophylaxis and therapy for viral hemorrhagic fevers. Cun: Opirr. Infect. Dis. (1990) 3:824–833.
   Google Scholar
• BANKS G, FERNANDEZ H: Clinical use of ribavirin in measles: a summarized review In: Clinical Applications of Ribavirin. Smith R, Knight V, Smith J (Eds.), Academic Press Inc., Orlando, USA (1984):203–209.
   Google Scholar
• FORNI A, SCHLUGER N, ROBERTS R: Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin. Infect. Dis. (1994) 19:454–462.
   PubMed Web of Science ®Google Scholar
• KAPLAN L, DAUM R, SMARON M, MACCARTHY C: Severe measles in immunocompromised patients. J. Arn. Med. A. (1992) 267:1237–1241.
   PubMed Web of Science ®Google Scholar
• SNELL N: New treatments for viral respiratory tract infections - opportunities and problems. j Aritlinicrob. Chernother. (2001) 47:251–259.
   PubMed Web of Science ®Google Scholar